Rxsight Inc (RXST)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $223.06M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rxsight Inc (RXST) Stock Forecast
Analysts expect Rxsight (RXST) to earn -$0.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $146.75M. Of 10 analysts, 1 rates the stock Buy or Strong Buy, 7 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 3.20, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 0 | 0.0% |
| Hold | 7 | 70.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 2 | 20.0% |
- Consensus
- Hold
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 21.1%.
- Fiscal year ending Dec 31, 2026
- -$0.13
- EPS consensus, revenue $146.75M
- Fiscal year ending Dec 31, 2027
- -$0.67
- EPS consensus, revenue $115.72M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.14 to -$0.10 | 3 | $146.75M | $143.07M to $149.00M | 10 |
| Dec 31, 2027 | -$0.67 | -$1.06 to -$0.41 | 5 | $115.72M | $106.02M to $123.00M | 10 |
Quarterly Estimates
The EPS consensus falls from $0.11 for the quarter ending Dec 31, 2026 to -$0.14 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.11 | -$0.31 to $0.26 | 12 | $58.68M | $52.77M to $62.79M | 12 |
| Mar 31, 2027 | -$0.14 | -$0.14 to -$0.13 | 2 | $29.64M | $26.32M to $32.60M | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.13 | -$0.13 | -$0.28 | -$0.27 | -$0.27 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.67 | -$0.73 | -$0.68 | -$0.70 | -$0.70 | N/A |
| Quarter ending Mar 31, 2027 | -$0.14 | -$0.11 | -$0.19 | -$0.19 | -$0.17 | N/A |
Frequently Asked Questions About RXST
What is the RXST stock forecast?
Consensus analyst estimates put Rxsight's EPS at -$0.13 for the fiscal year ending Dec 31, 2026, on revenue of $146.75M. The consensus rating from 10 analysts is Hold.
How do analysts rate RXST stock?
Of 10 analysts covering Rxsight, 1 rates it Strong Buy, 0 Buy, 7 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from RXST next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.13, with estimates from -$0.14 to -$0.10 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.67, with estimates from -$1.06 to -$0.41 from 5 analysts.
What revenue do analysts expect from Rxsight next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $146.75M, with estimates from $143.07M to $149.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $115.72M, with estimates from $106.02M to $123.00M.
How many analysts cover RXST?
10 analysts rate Rxsight stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RXST pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors